Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.83 HKD | 0.00% | 0.00% | -9.78% |
30/04 | LH Group Limited Announces Board and Committee Changes | CI |
29/04 | Labcorp Receives US FDA's Approval for Companion Diagnostic Device for Use With Pfizer's Hemophilia B Gene Therapy | MT |
Sales 2022 | 106.72Cr 14Cr 1.14TCr | Sales 2023 | 128.01Cr 16Cr 1.37TCr | Capitalization | 74Cr 9.42Cr 786.18Cr |
---|---|---|---|---|---|
Net income 2022 | 7.7Cr 98.57L 82Cr | Net income 2023 | 8.8Cr 1.13Cr 94Cr | EV / Sales 2022 | 0.69 x |
Net cash position 2022 | 12Cr 1.51Cr 126.32Cr | Net Debt 2023 | 24.61L 3L 2.63Cr | EV / Sales 2023 | 0.58 x |
P/E ratio 2022 |
11
x | P/E ratio 2023 |
8.36
x | Employees | 1,667 |
Yield 2022 |
7.26% | Yield 2023 |
9.58% | Free-Float | 25% |
1 month | -1.19% | ||
3 months | -7.78% | ||
6 months | -17.82% | ||
Current year | -9.78% |
Managers | Title | Age | Since |
---|---|---|---|
Kit Lung Wong
CEO | Chief Executive Officer | 50 | 20/17/20 |
Dong John Yang
DFI | Director of Finance/CFO | 49 | 11/23/11 |
Hiu Yi Chan
ADM | Chief Administrative Officer | 38 | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Wai Man Hung
BRD | Director/Board Member | 55 | 30/18/30 |
Kit Lung Wong
CEO | Chief Executive Officer | 50 | 20/17/20 |
Sau Chee Ko
BRD | Director/Board Member | 58 | 20/17/20 |
Date | Price | Change | Volume |
---|---|---|---|
13/24/13 | 0.83 | 0.00% | 456 000 |
10/24/10 | 0.83 | 0.00% | 962,000 |
09/24/09 | 0.83 | +1.22% | 846,000 |
08/24/08 | 0.82 | 0.00% | 46,000 |
07/24/07 | 0.82 | -1.20% | 382,000 |
Delayed Quote Hong Kong S.E., May 13, 2024 at 01:38 pm IST
More quotesAnnual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-9.78% | 8.5Cr | |
+34.98% | 1.12TCr | |
+18.33% | 875.5Cr | |
+39.75% | 261.69Cr | |
+6.28% | 225.49Cr | |
+11.57% | 191.86Cr | |
+12.50% | 176.44Cr | |
-0.18% | 146Cr | |
-17.15% | 94Cr | |
-3.21% | 79Cr |
- Stock Market
- Equities
- 1978 Stock